55.81
price up icon1.64%   0.84
 
loading
전일 마감가:
$54.97
열려 있는:
$54.64
하루 거래량:
932.71K
Relative Volume:
0.47
시가총액:
$11.02B
수익:
$2.95B
순이익/손실:
$523.88M
주가수익비율:
20.75
EPS:
2.69
순현금흐름:
$620.18M
1주 성능:
+2.16%
1개월 성능:
-3.79%
6개월 성능:
-15.00%
1년 성능:
-31.97%
1일 변동 폭
Value
$54.62
$56.66
1주일 범위
Value
$53.76
$56.66
52주 변동 폭
Value
$52.93
$94.85

바이오마린 Stock (BMRN) Company Profile

Name
명칭
Biomarin Pharmaceutical Inc
Name
전화
(415) 506-6700
Name
주소
105 DIGITAL DRIVE, NOVATO, CA
Name
직원
3,040
Name
트위터
Name
다음 수익 날짜
2024-10-29
Name
최신 SEC 제출 서류
Name
BMRN's Discussions on Twitter

BMRN을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
BMRN
Biomarin Pharmaceutical Inc
55.84 11.02B 2.95B 523.88M 620.18M 2.69
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
452.50 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
538.26 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
324.19 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
554.80 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.50 28.51B 3.81B -644.79M -669.77M -6.24

바이오마린 Stock (BMRN) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-02-24 업그레이드 Oppenheimer Perform → Outperform
2024-11-15 개시 Wolfe Research Outperform
2024-10-30 다운그레이드 William Blair Outperform → Mkt Perform
2024-10-10 재개 Raymond James Outperform
2024-08-20 업그레이드 Bernstein Mkt Perform → Outperform
2024-05-17 다운그레이드 Robert W. Baird Outperform → Neutral
2024-05-14 개시 Evercore ISI Outperform
2023-11-15 개시 Wells Fargo Overweight
2023-10-23 업그레이드 Bernstein Underperform → Mkt Perform
2023-09-28 개시 Raymond James Mkt Perform
2023-09-18 개시 UBS Buy
2023-07-27 개시 Scotiabank Sector Perform
2023-07-05 업그레이드 BMO Capital Markets Market Perform → Outperform
2023-06-14 재개 Credit Suisse Outperform
2023-03-21 개시 Bernstein Underperform
2023-02-22 다운그레이드 Oppenheimer Outperform → Perform
2023-02-21 개시 Citigroup Neutral
2023-01-30 개시 BMO Capital Markets Market Perform
2023-01-18 개시 Canaccord Genuity Hold
2022-10-31 업그레이드 Oppenheimer Perform → Outperform
2022-07-13 개시 Cantor Fitzgerald Overweight
2022-06-13 재개 Wedbush Neutral
2022-04-25 업그레이드 Morgan Stanley Equal-Weight → Overweight
2021-11-22 업그레이드 William Blair Mkt Perform → Outperform
2021-10-07 재개 Jefferies Buy
2021-09-09 업그레이드 Stifel Hold → Buy
2021-06-04 재개 Robert W. Baird Outperform
2021-04-26 재개 Credit Suisse Outperform
2021-03-04 재개 Guggenheim Buy
2021-03-01 업그레이드 Evercore ISI In-line → Outperform
2020-08-20 다운그레이드 Citigroup Buy → Neutral
2020-08-20 다운그레이드 William Blair Outperform → Mkt Perform
2020-08-19 다운그레이드 Evercore ISI Outperform → In-line
2020-08-19 다운그레이드 RBC Capital Mkts Outperform → Sector Perform
2020-08-19 다운그레이드 Stifel Buy → Hold
2020-07-08 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2020-07-06 재확인 Citigroup Buy
2020-01-28 개시 BMO Capital Markets Market Perform
2020-01-27 개시 BMO Capital Markets Market Perform
2020-01-24 업그레이드 RBC Capital Mkts Sector Perform → Outperform
2019-11-27 업그레이드 Barclays Equal Weight → Overweight
2019-11-12 개시 SunTrust Buy
2019-10-17 재개 BofA/Merrill Buy
2019-05-23 재개 Citigroup Buy
2019-04-09 재개 Raymond James Outperform
2019-01-02 다운그레이드 Raymond James Outperform → Mkt Perform
2018-12-14 개시 Wolfe Research Outperform
2018-10-01 개시 Cantor Fitzgerald Overweight
2018-08-07 재확인 Stifel Buy
2018-08-03 재확인 Stifel Buy
모두보기

바이오마린 주식(BMRN)의 최신 뉴스

pulisher
Jun 18, 2025

BioMarin Generates Patient Experience Data With Early And Often Engagement - Clinical Leader

Jun 18, 2025
pulisher
Jun 15, 2025

Jim Cramer on BioMarin: “I Don’t Think It Works Now” - MSN

Jun 15, 2025
pulisher
Jun 14, 2025

BioMarin’s SWOT analysis: stock growth potential amid rare disease focus - Investing.com

Jun 14, 2025
pulisher
Jun 13, 2025

BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz - MSN

Jun 13, 2025
pulisher
Jun 12, 2025

Jim Cramer Discussed These 16 Stocks Recently - Insider Monkey

Jun 12, 2025
pulisher
Jun 12, 2025

Phenylktonuria Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Erytech Pharma SA, Homology Medicines Inc., Synlogic Inc., BioMarin Pharmaceuticals - Barchart.com

Jun 12, 2025
pulisher
Jun 12, 2025

Jim Cramer Is All Aboard Union Pacific, But Shows No Love For Orphan Drugs - Benzinga

Jun 12, 2025
pulisher
Jun 09, 2025

Morquio Syndrome (MPS-IV) Drug Market Is Booming So Rapidly - openPR.com

Jun 09, 2025
pulisher
Jun 05, 2025

Here Are All 6 Stocks I've Bought Through 5 Months of 2025 - The Motley Fool

Jun 05, 2025
pulisher
Jun 05, 2025

The Top 12 Companies Hiring in Biopharma Now - BioSpace

Jun 05, 2025
pulisher
Jun 04, 2025

Marin Awareness Walk Draws Over 100 Community Members - Patch

Jun 04, 2025
pulisher
Jun 02, 2025

inozyme pharma announces executive bonuses amid merger plans By Investing.com - Investing.com Nigeria

Jun 02, 2025
pulisher
Jun 02, 2025

inozyme pharma announces executive bonuses amid merger plans - Investing.com

Jun 02, 2025
pulisher
May 30, 2025

BioMarin Now Targets $3 Bln Revenue Goal For 2025 - RTTNews

May 30, 2025
pulisher
May 30, 2025

The past five years for BioMarin Pharmaceutical (NASDAQ:BMRN) investors has not been profitable - simplywall.st

May 30, 2025
pulisher
May 29, 2025

Is the Options Market Predicting a Spike in BioMarin Pharmaceutical Stock? - MSN

May 29, 2025
pulisher
May 28, 2025

Is The Options Market Predicting A Spike In BioMarin Pharmaceutical Stock? - Barchart.com

May 28, 2025
pulisher
May 28, 2025

Noonan Syndrome Market Growth to Accelerate in Forecast Period (2023-2032), DelveInsight Analyzes | Novo Nordisk A/S, BioMarin Pharma - The Globe and Mail

May 28, 2025
pulisher
May 27, 2025

FDA issues BioMarin complete response letter for Duchenne muscular dystrophy drug Kyndrisa - FirstWord Pharma

May 27, 2025
pulisher
May 27, 2025

Stifel maintains Buy on BioMarin, price target at $91 By Investing.com - Investing.com India

May 27, 2025
pulisher
May 27, 2025

Stifel maintains Buy on BioMarin, price target at $91 - Investing.com

May 27, 2025
pulisher
May 26, 2025

Phenylktonuria Treatment Market Overall Study Report - openPR.com

May 26, 2025
pulisher
May 26, 2025

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock - Yahoo Finance

May 26, 2025
pulisher
May 25, 2025

BioMarin’s SWOT analysis: genetic medicine firm’s stock shows growth potential - Investing.com

May 25, 2025
pulisher
May 24, 2025

Biotech Stock Roundup: BMRN to Acquire INZY, NVAX Gains on Vaccine Approval & More - MSN

May 24, 2025
pulisher
May 24, 2025

Inozyme Stock Rockets 179% After BioMarin Agrees To Acquire The Company For $270M: Retail Sentiment Brightens - MSN

May 24, 2025
pulisher
May 23, 2025

Rx Rundown: BioMarin, Novavax, CellCentric and more - Medical Marketing and Media

May 23, 2025
pulisher
May 22, 2025

BioMarin Pharmaceutical Approves Equity Plan Amendment - TipRanks

May 22, 2025
pulisher
May 22, 2025

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio - Yahoo

May 22, 2025
pulisher
May 22, 2025

Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), ACADIA Pharmaceuticals (ACAD) and Quanterix (QTRX) - The Globe and Mail

May 22, 2025
pulisher
May 21, 2025

BioMarin’s Acquisition of Inozyme Pharma - Global Legal Chronicle

May 21, 2025
pulisher
May 21, 2025

INOZYME PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inozyme Pharma, Inc.INZY - Business Wire

May 21, 2025
pulisher
May 21, 2025

6,941 Shares in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Acquired by Focus Partners Wealth - Defense World

May 21, 2025
pulisher
May 21, 2025

BioMarin agrees to acquire Inozyme for $270m - MSN

May 21, 2025
pulisher
May 20, 2025

Insider Sell Alert: Erin Burkhart Sells Shares of Biomarin Pharmaceutical Inc (BMRN) - GuruFocus

May 20, 2025
pulisher
May 19, 2025

Is this European biotech’s moment? — a BioCentury podcast - biocentury.com

May 19, 2025
pulisher
May 19, 2025

BioMarin Expands Rare Disease Portfolio with $270M Inozyme Acquisition - MSN

May 19, 2025
pulisher
May 19, 2025

BioMarin to buy enzyme therapy developer Inozyme in $270M all-cash deal - MSN

May 19, 2025
pulisher
May 19, 2025

Inozyme Pharma finds buyer in BioMarin after strategic review - The Business Journals

May 19, 2025
pulisher
May 19, 2025

Bernstein raises BioMarin stock target to $95, maintains Outperform - Investing.com Australia

May 19, 2025
pulisher
May 19, 2025

Bernstein raises BioMarin stock target to $95, maintains Outperform By Investing.com - Investing.com Nigeria

May 19, 2025
pulisher
May 19, 2025

BioMarin: Inozyme Acquisition Falls Short Of Offsetting Looming Revenue Risks (Downgrade) - Seeking Alpha

May 19, 2025
pulisher
May 19, 2025

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Given Average Rating of “Moderate Buy” by Brokerages - Defense World

May 19, 2025
pulisher
May 18, 2025

BioMarin Buying Inozyme Pharma In $270 Million Deal - Pulse 2.0

May 18, 2025
pulisher
May 18, 2025

StockWatch: With Inozyme Buyout, BioMarin Pursues Growth via M&A - Genetic Engineering and Biotechnology News

May 18, 2025

바이오마린 (BMRN) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$20.90
price up icon 1.31%
$35.76
price down icon 0.62%
$21.32
price down icon 0.15%
$98.61
price down icon 1.98%
$108.80
price up icon 2.21%
biotechnology ONC
$246.51
price up icon 1.76%
자본화:     |  볼륨(24시간):